CN114929867A - 一种经修饰的免疫效应细胞及其用途 - Google Patents
一种经修饰的免疫效应细胞及其用途 Download PDFInfo
- Publication number
- CN114929867A CN114929867A CN202180009125.9A CN202180009125A CN114929867A CN 114929867 A CN114929867 A CN 114929867A CN 202180009125 A CN202180009125 A CN 202180009125A CN 114929867 A CN114929867 A CN 114929867A
- Authority
- CN
- China
- Prior art keywords
- cell
- constant region
- activity
- expression
- immune effector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012642 immune effector Substances 0.000 title claims abstract description 206
- 229940121354 immunomodulator Drugs 0.000 title claims abstract description 206
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 368
- 210000004027 cell Anatomy 0.000 claims abstract description 362
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 345
- 230000000694 effects Effects 0.000 claims abstract description 296
- 102100032272 T cell receptor delta constant Human genes 0.000 claims abstract description 156
- 101710205572 T cell receptor delta constant Proteins 0.000 claims abstract description 150
- 230000001105 regulatory effect Effects 0.000 claims abstract description 116
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 93
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 90
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 73
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims abstract description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 117
- 108020004707 nucleic acids Proteins 0.000 claims description 113
- 102000039446 nucleic acids Human genes 0.000 claims description 113
- 150000007523 nucleic acids Chemical class 0.000 claims description 113
- 230000002222 downregulating effect Effects 0.000 claims description 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108010031480 Artificial Receptors Proteins 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 19
- 108091033409 CRISPR Proteins 0.000 claims description 16
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 10
- 230000000139 costimulatory effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 210000002540 macrophage Anatomy 0.000 claims description 10
- 210000001616 monocyte Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 8
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- -1 LIGHT Proteins 0.000 claims description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 102100038078 CD276 antigen Human genes 0.000 claims description 6
- 101710185679 CD276 antigen Proteins 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 6
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 6
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 6
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 6
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 6
- 101001050318 Homo sapiens Junctional adhesion molecule-like Proteins 0.000 claims description 6
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 6
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims description 6
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims description 6
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 102100023437 Junctional adhesion molecule-like Human genes 0.000 claims description 6
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 238000010357 RNA editing Methods 0.000 claims description 3
- 230000026279 RNA modification Effects 0.000 claims description 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 238000010459 TALEN Methods 0.000 claims description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 230000030279 gene silencing Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000002924 silencing RNA Substances 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims 2
- 108700010039 chimeric receptor Proteins 0.000 description 66
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 22
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 22
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 21
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 16
- 238000001890 transfection Methods 0.000 description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 101000679306 Homo sapiens T cell receptor gamma constant 1 Proteins 0.000 description 10
- 102100022590 T cell receptor gamma constant 1 Human genes 0.000 description 10
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 108020005004 Guide RNA Proteins 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 6
- 101000798076 Homo sapiens T cell receptor delta constant Proteins 0.000 description 6
- 101000679307 Homo sapiens T cell receptor gamma constant 2 Proteins 0.000 description 6
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 6
- 101100098621 Paramecium tetraurelia T2A gene Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241000193996 Streptococcus pyogenes Species 0.000 description 6
- 102100022571 T cell receptor gamma constant 2 Human genes 0.000 description 6
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 102220003351 rs387906411 Human genes 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 229940127174 UCHT1 Drugs 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009258 tissue cross reactivity Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 230000008265 DNA repair mechanism Effects 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 208000004605 Persistent Truncus Arteriosus Diseases 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 208000037258 Truncus arteriosus Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010002591 epsilon receptor Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 101150038336 T2A gene Proteins 0.000 description 1
- 101150077364 TRDC gene Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000003568 cytokine secretion assay Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
提供了一种经修饰的免疫效应细胞，其中与未经所述修饰的相应细胞中相应蛋白质的表达和/或活性相比，T细胞受体α恒定区蛋白和T细胞受体β恒定区蛋白中至少一个的表达和/或活性被下调，且T细胞受体γ恒定区蛋白的跨膜区和T细胞受体δ恒定区蛋白的跨膜区的表达和/或活性被上调。还提供了所述经修饰的免疫效应细胞的制备方法和用途。
Description
PCT国内申请，说明书已公开。
Claims (78)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020100718169 | 2020-01-21 | ||
| CN202010071816 | 2020-01-21 | ||
| PCT/CN2021/072844 WO2021147891A1 (zh) | 2020-01-21 | 2021-01-20 | 一种经修饰的免疫效应细胞及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114929867A true CN114929867A (zh) | 2022-08-19 |
Family
ID=76992058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180009125.9A Pending CN114929867A (zh) | 2020-01-21 | 2021-01-20 | 一种经修饰的免疫效应细胞及其用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114929867A (zh) |
| WO (1) | WO2021147891A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08149981A (ja) * | 1993-12-13 | 1996-06-11 | La Jolla Inst For Allergy & Immunology | Ｔ細胞α鎖による抗原特異的免疫制御の方法 |
| ES2983094T3 (es) * | 2014-10-31 | 2024-10-21 | Univ Pennsylvania | Alteración de la expresión génica en células CAR-T y usos de los mismos |
| CN109694854B (zh) * | 2017-10-20 | 2023-11-21 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| EP3775229A4 (en) * | 2018-03-27 | 2021-12-15 | The Trustees Of The University Of Pennsylvania | MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTIONS AND SCREENING PROCEDURES FOR THIS |
| CN110343667A (zh) * | 2019-07-17 | 2019-10-18 | 贝赛尔特(北京)生物技术有限公司 | 工程化的免疫细胞及其制备方法和应用 |
-
2021
- 2021-01-20 WO PCT/CN2021/072844 patent/WO2021147891A1/zh active Application Filing
- 2021-01-20 CN CN202180009125.9A patent/CN114929867A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021147891A1 (zh) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210253726A1 (en) | Car expression vector and car-expressing t cells | |
| JP7190096B2 (ja) | 遺伝子編集ｔ細胞及びその使用 | |
| TW202134264A (zh) | 嵌合抗原受體及其用途 | |
| CN111566124A (zh) | 制备表达嵌合抗原受体的细胞的方法 | |
| JP7412666B2 (ja) | ＨＰＫ１を標的とするｇＲＮＡ及びＨＰＫ１遺伝子の編集方法 | |
| KR20200000495A (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
| WO2019154313A1 (zh) | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 | |
| KR20200079312A (ko) | 면역요법을 위한 t 세포 내 cblb의 crispr-cas9 편집 방법, 조성물 및 성분 | |
| WO2018068257A1 (zh) | 通用型car-t细胞及其制备方法和用途 | |
| JP2022512450A (ja) | Ｇｐｃ３を標的とする免疫エフェクター細胞およびその応用 | |
| CN113122504A (zh) | 一种纯化ucart细胞的方法与应用 | |
| CN113122503A (zh) | 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用 | |
| TW202140790A (zh) | 病毒載體轉導細胞的方法 | |
| CN114891123B (zh) | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 | |
| EP4086341A1 (en) | Method for purifying ucart cell and use thereof | |
| CN117642510A (zh) | 靶向her2的通用型car-t细胞及其制备方法 | |
| WO2021147891A1 (zh) | 一种经修饰的免疫效应细胞及其用途 | |
| US20230059884A1 (en) | Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof | |
| WO2023274386A1 (zh) | 靶向egfr的通用型car-t细胞及其制备方法 | |
| CN118374456A (zh) | 改造的免疫细胞、靶向BRD9基因的gRNA和应用 | |
| CN117165529A (zh) | 一种经过基因修饰的t细胞及其制备方法和应用 | |
| WO2023222617A1 (en) | Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof | |
| CN117778328A (zh) | 一种通用型bcma car-t细胞的增殖方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075898 Country of ref document: HK |